Glucose metabolism outcomes after pituitary surgery in patients with acromegaly.

Acromegaly Diabetes mellitus Glucose levels HbA1c Pituitary adenoma Remission Somatotropinoma

Journal

Pituitary

ISSN: 1573-7403

Titre abrégé: Pituitary

Pays: United States

ID NLM: 9814578

Informations de publication

Date de publication:
28 Jun 2024

Historique:

accepted: 15 06 2024

medline: 28 6 2024

pubmed: 28 6 2024

entrez: 28 6 2024

Statut: aheadofprint

Résumé

To investigate the impact of pituitary surgery on glucose metabolism and to identify predictors of remission of diabetes after pituitary surgery in patients with acromegaly. A national multicenter retrospective study of patients with acromegaly undergoing transsphenoidal surgery for the first time at 33 tertiary Spanish hospitals (ACRO-SPAIN study) was performed. Surgical remission of acromegaly was evaluated according to the 2000 and 2010 criteria. A total of 604 acromegaly patients were included in the study with a total median follow up of 91 months (interquartile range [IQR] 45-163). At the acromegaly diagnosis, 23.8% of the patients had diabetes mellitus (DM) with a median glycated hemoglobin (HbA1c) of 6.9% (IQR 6.4-7.9) [51.9 mmol/mol (IQR 46.4-62.8)]. In the multivariate analysis, older age (odds ratio [OR] 1.02, 95% CI 1.00-1.05), dyslipidemia (OR 5.25, 95% CI 2.81 to 9.79), arthropathy (OR 1.39, 95% CI 2.82 to 9.79), and higher IGF-I levels (OR 1.30, 95% CI 1.05 to 1.60) were associated with a greater prevalence of DM. At the last follow-up visit after surgery, 21.1% of the DM patients (56.7% of them with surgical remission of acromegaly) experienced diabetes remission. The cure rate of DM was more common in older patients (hazard ratio [HR] 1.77, 95% CI 1.31 to 2.43), when surgical cure was achieved (HR 2.10, 95% CI 1.01 to 4.37) and when anterior pituitary function was not affected after surgery (HR 3.38, 95% CI 1.17 to 9.75). Glucose metabolism improved in patients with acromegaly after surgery and 21% of the diabetic patients experienced diabetes remission; being more frequent in patients of older age, and those who experienced surgical cure and those with preserved anterior pituitary function after surgery.

Identifiants

DOI: 10.1007/s11102-024-01415-x PMID: 38940859

pubmed: 38940859

doi: 10.1007/s11102-024-01415-x

pii: 10.1007/s11102-024-01415-x

doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

Informations de copyright

Références

Melmed S (2009) Acromegaly pathogenesis and treatment. J Clin Invest 119(11):3189–3202

doi: 10.1172/JCI39375 pubmed: 19884662 pmcid: 2769196

Abreu A, Tovar AP, Castellanos R, Valenzuela A, Giraldo CM, Pinedo AC et al (2016) Challenges in the diagnosis and management of acromegaly: a focus on comorbidities. Pituitary 19(4):448–457

doi: 10.1007/s11102-016-0725-2 pubmed: 27279011 pmcid: 4935749

Hannon AM, Thompson CJ, Sherlock M (2017) Diabetes in patients with acromegaly. Curr Diab Rep 17(2):8

doi: 10.1007/s11892-017-0838-7 pubmed: 28150161

Rodrigues TC, Costenaro F, Fedrizzi D, Oliveira MD, Lima PB, Boschi V et al (2011) Diabetes mellitus in a cohort of patients with acromegaly. Arq Bras Endocrinol Metabol 55(9):714–719

doi: 10.1590/S0004-27302011000900008 pubmed: 22231975

Jonas C, Maiter D, Alexopoulou O (2016) Evolution of glucose tolerance after treatment of Acromegaly: a study in 57 patients. Horm Metab Res 48(5):299–305

doi: 10.1055/s-0035-1569277 pubmed: 26849822

Fieffe S, Morange I, Petrossians P, Chanson P, Rohmer V, Cortet C et al (2011) Diabetes in acromegaly, prevalence, risk factors, and evolution: data from the French Acromegaly Registry. Eur J Endocrinol 164(6):877–884

doi: 10.1530/EJE-10-1050 pubmed: 21464140

Alexopoulou O, Bex M, Kamenicky P, Mvoula AB, Chanson P, Maiter D (2014) Prevalence and risk factors of impaired glucose tolerance and diabetes mellitus at diagnosis of acromegaly: a study in 148 patients. Pituitary 17(1):81–89

doi: 10.1007/s11102-013-0471-7 pubmed: 23446424

Clemmons DR (2002) Roles of insulin-like growth factor-I and growth hormone in mediating insulin resistance in acromegaly. Pituitary 5(3):181–183

doi: 10.1023/A:1023321421760 pubmed: 12812310

Katznelson L, Laws ER Jr., Melmed S, Molitch ME, Murad MH, Utz A et al (2014) Acromegaly: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 99(11):3933–3951

doi: 10.1210/jc.2014-2700 pubmed: 25356808

Melmed S (2006) Medical progress: Acromegaly. N Engl J Med 355(24):2558–2573

doi: 10.1056/NEJMra062453 pubmed: 17167139

Jaffrain-Rea ML, Minniti G, Moroni C, Esposito V, Ferretti E, Santoro A et al (2003) Impact of successful transsphenoidal surgery on cardiovascular risk factors in acromegaly. Eur J Endocrinol 148(2):193–201

doi: 10.1530/eje.0.1480193 pubmed: 12590638

Kinoshita Y, Fujii H, Takeshita A, Taguchi M, Miyakawa M, Oyama K et al (2011) Impaired glucose metabolism in Japanese patients with acromegaly is restored after successful pituitary surgery if pancreatic beta-cell function is preserved. Eur J Endocrinol 164(4):467–473

doi: 10.1530/EJE-10-1096 pubmed: 21285083

Tzanela M, Vassiliadi DA, Gavalas N, Szabo A, Margelou E, Valatsou A et al (2011) Glucose homeostasis in patients with acromegaly treated with surgery or somatostatin analogues. Clin Endocrinol (Oxf) 75(1):96–102

doi: 10.1111/j.1365-2265.2011.03996.x pubmed: 21521267

He W, Yan L, Wang M, Li Q, He M, Ma Z et al (2019) Surgical outcomes and predictors of glucose metabolism alterations for growth hormone-secreting pituitary adenomas: a hospital-based study of 151 cases. Endocrine 63(1):27–35

doi: 10.1007/s12020-018-1745-7 pubmed: 30238327

Araujo-Castro M, Biagetti B, Menendez Torre E, Novoa-Testa I, Cordido F, Pascual Corrales E et al (2024) Differences between GH and PRL co-secreting and GH-secreting pituitary adenomas. A series of 604 cases. J Clin Endocrinol Metab

Fleseriu M, Biller BMK, Freda PU, Gadelha MR, Giustina A, Katznelson L et al (2021) A Pituitary Society update to acromegaly management guidelines. Pituitary 24(1):1–13

doi: 10.1007/s11102-020-01091-7 pubmed: 33079318

Giustina A, Barkan A, Casanueva FF, Cavagnini F, Frohman L, Ho K et al (2000) Criteria for cure of acromegaly: a consensus statement. J Clin Endocrinol Metab 85(2):526–529

pubmed: 10690849

Giustina A, Chanson P, Bronstein MD, Klibanski A, Lamberts S, Casanueva FF et al (2010) A consensus on criteria for cure of acromegaly. J Clin Endocrinol Metab 95(7):3141–3148

doi: 10.1210/jc.2009-2670 pubmed: 20410227

ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D et al (2023) 2. Classification and diagnosis of diabetes: standards of Care in Diabetes-2023. Diabetes Care 46(Suppl 1):S19–S40

doi: 10.2337/dc23-S002 pubmed: 36507649

Riddle MC, Cefalu WT, Evans PH, Gerstein HC, Nauck MA, Oh WK et al (2021) Consensus Report: definition and interpretation of Remission in Type 2 diabetes. Diabetes Care 44(10):2438–2444

doi: 10.2337/dci21-0034 pubmed: 34462270 pmcid: 8929179

Obesity (2000) Preventing and managing the global epidemic. Report of a WHO consultation. World Health Organ Tech Rep Ser 894:i–xii

Magliano DJ, Boyko EJ (2021) IDF DIABETES ATLAS. IDF Diabetes Atlas. 10th ed. Brussels

Colao A, Ferone D, Marzullo P, Lombardi G (2004) Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr Rev 25(1):102–152

doi: 10.1210/er.2002-0022 pubmed: 14769829

Li YL, Zhang S, Guo XP, Gao L, Lian W, Yao Y et al (2019) Correlation analysis between short-term insulin-like growth factor-I and glucose intolerance status after transsphenoidal adenomectomy in acromegalic patients: a large retrospective study from a single center in China. Arch Endocrinol Metab 63(2):157–166

pubmed: 30916168 pmcid: 10522129

Moller N, Jorgensen JO (2009) Effects of growth hormone on glucose, lipid, and protein metabolism in human subjects. Endocr Rev 30(2):152–177

doi: 10.1210/er.2008-0027 pubmed: 19240267

Li X, Tang J, Lin S, Liu X, Li Y (2024) Mendelian randomization analysis demonstrates the causal effects of IGF family members in diabetes. Front Med (Lausanne) 11:1332162

doi: 10.3389/fmed.2024.1332162 pubmed: 38375323

Sandhu MS (2005) Insulin-like growth factor-I and risk of type 2 diabetes and coronary heart disease: molecular epidemiology. Endocr Dev 9:44–54

doi: 10.1159/000085755 pubmed: 15879687

Helseth R, Carlsen SM, Bollerslev J, Svartberg J, Oksnes M, Skeie S et al (2016) Preoperative octreotide therapy and surgery in acromegaly: associations between glucose homeostasis and treatment response. Endocrine 51(2):298–307

doi: 10.1007/s12020-015-0679-6 pubmed: 26179177

Colao A, Attanasio R, Pivonello R, Cappabianca P, Cavallo LM, Lasio G et al (2006) Partial surgical removal of growth hormone-secreting pituitary tumors enhances the response to somatostatin analogs in acromegaly. J Clin Endocrinol Metab 91(1):85–92

doi: 10.1210/jc.2005-1208 pubmed: 16263832

Colao A, Auriemma RS, Galdiero M, Cappabianca P, Cavallo LM, Esposito F et al (2009) Impact of somatostatin analogs versus surgery on glucose metabolism in acromegaly: results of a 5-year observational, open, prospective study. J Clin Endocrinol Metab 94(2):528–537

doi: 10.1210/jc.2008-1546 pubmed: 19001517

Ronchi CL, Varca V, Beck-Peccoz P, Orsi E, Donadio F, Baccarelli A et al (2006) Comparison between six-year therapy with long-acting somatostatin analogs and successful surgery in acromegaly: effects on cardiovascular risk factors. J Clin Endocrinol Metab 91(1):121–128

doi: 10.1210/jc.2005-1704 pubmed: 16263816

Moller N, Schmitz O, Joorgensen JO, Astrup J, Bak JF, Christensen SE et al (1992) Basal- and insulin-stimulated substrate metabolism in patients with active acromegaly before and after adenomectomy. J Clin Endocrinol Metab 74(5):1012–1019

pubmed: 1569148

Stelmachowska-Banas M, Zielinski G, Zdunowski P, Podgorski J, Zgliczynski W (2011) The impact of transsphenoidal surgery on glucose homeostasis and insulin resistance in acromegaly. Neurol Neurochir Pol 45(4):328–334

doi: 10.1016/S0028-3843(14)60103-1 pubmed: 22101993

Espinosa-de-los-Monteros AL, Gonzalez B, Vargas G, Sosa E, Mercado M (2011) Clinical and biochemical characteristics of acromegalic patients with different abnormalities in glucose metabolism. Pituitary 14(3):231–235

doi: 10.1007/s11102-010-0284-x pubmed: 21161601

Cozzolino A, Feola T, Simonelli I, Puliani G, Pozza C, Giannetta E et al (2018) Somatostatin analogs and glucose metabolism in Acromegaly: a Meta-analysis of prospective interventional studies. J Clin Endocrinol Metab

Mazziotti G, Floriani I, Bonadonna S, Torri V, Chanson P, Giustina A (2009) Effects of somatostatin analogs on glucose homeostasis: a metaanalysis of acromegaly studies. J Clin Endocrinol Metab 94(5):1500–1508

doi: 10.1210/jc.2008-2332 pubmed: 19208728

Mazziotti G, Marzullo P, Doga M, Aimaretti G, Giustina A (2015) Growth hormone deficiency in treated acromegaly. Trends Endocrinol Metab 26(1):11–21

doi: 10.1016/j.tem.2014.10.005 pubmed: 25434492

Gonzalez B, Vargas G, de Los Monteros ALE, Mendoza V, Mercado M (2018) Persistence of diabetes and hypertension after Multimodal Treatment of Acromegaly. J Clin Endocrinol Metab 103(6):2369–2375

doi: 10.1210/jc.2018-00325 pubmed: 29618021

Asa SL, Mete O, Perry A, Osamura RY (2022) Overview of the 2022 WHO classification of Pituitary tumors. Endocr Pathol 33(1):6–26

doi: 10.1007/s12022-022-09703-7 pubmed: 35291028